AR and prostate cancer: To investigate the regulation of SRARP and HSPB7 expression in malignancies, a broad group of cancer cell lines were applied that included breast cancer lines T‐47D (ER+/AR+), MFM‐223 (ER−/AR+), MDA‐MB‐231 (ER−/AR−), and MDA‐MB‐468 (ER−/AR−); prostate cancer line DU‐145 (AR‐independent); renal carcinoma lines 786‐0 and A498; UACC‐257 (melanoma); U‐2 OS (osteosarcoma); IGROV1 (ovarian cancer); Ishikawa (endometrial cancer); A549 (non‐small‐cell lung cancer); HCT‐15 (colorectal cancer); and GBM line SF‐268 (Table 3).